Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (14): 2585-2588.doi: 10.3969/j.issn.1673-8225.2012.14.024

Previous Articles     Next Articles

Short-term effects of human umbilical cord-derived mesenchymal stem cells in treatment of patients with decompensated cirrhosis   

Zhang Yue-fan1, Li Nan2, Zhai Jun-shan2, Jiang Li-jun2, Cao Jian-ning3   

  1. 1Postgraduate Medical School of Chinese PLA, Beijing  100853, China; 2Department of Gastroenterology, the 309th Hospital of ChinesePLA, Beijing  100091, China; 3 Beike Bio- Technology Co., Ltd., Shenzhen  518057, Guangdong Province, China
  • Received:2011-10-09 Revised:2011-11-18 Online:2012-04-01 Published:2012-04-01
  • Contact: author: Li Nan, Doctor, Chief physician, Doctoral supervisor, Department of Gastroenterology, the 309th Hospital of Chinese PLA, Beijing 100091, China linan957@sina.com
  • About author:Zhang Yue-fan★, Studying for master’s degree, Postgraduate Medical School of Chinese PLA, Beijing 100853, China zyf490@163.com
  • Supported by:

    Wu Jieping Medical Foundation, No. 320.6710.10001*

PDF

433

Abstract:

BACKGROUND: Umbilical cord-derived mesenchymal stem cells (UCMSCs) can differentiate into hapatocyte-like cells.
OBJECTIVE: To investigate short-time clinical effects of UCMSCs transplantation in treatment of patients with decompensated cirrhosis.
METHODS: Thirty patients with decompensated cirrhosis were involved. Eighteen patients in the control group were treated with conventional therapy, while twelve patients in the transplantation group were treated with UCMSCs transplantation via hepatic artery based on conventional therapy.
RESULTS AND CONCLUSION: After transplantation, albumin level in the transplantation group showed an ascend trend and had a significant increase (P < 0.05) compared with the control group from 2 weeks to 12 weeks of transplantation. Meanwhile, both alanine aminotransferase and prothrombin time levels began to decrease at 2 weeks after transplantation and were significantly lower than those of the control group (P < 0.05) from 8 weeks to 12 weeks of transplantation. In contrast to the controls, the level of total bilirubin in the transplantation group showed an ascend trend and had a significant increase (P < 0.05) from 4 weeks to 12 weeks of transplantation. The differences in clinical symptoms and signs between the two groups were not significant (P > 0.05). The transplantation of UC-MSCs via hepatic artery is effective in short time for treatment of patients with decompensated cirrhosis.

CLC Number: